Document 2650
 DOCN  M94A2650
 TI    HIV-specific IgG3 for early detection of uninfected children born to
       HIV-infected mothers.
 DT    9412
 AU    Caselli D; Maccabruni A; Marconi M; Pasinetti G; Stronati M; Bossi G;
       Arico M; Dept. of Pediatrics, University of Pavia, IRCCS Policlinico
       San; Matteo & Neonatology, Osp. Riuniti, Bergamo, Italy.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):256 (abstract no. PB0455). Unique
       Identifier : AIDSLINE ICA10/94369925
 AB    BACKGROUND: we still lack a simple, low cost test for early
       identification of uninfected children born to HIV seropositive mothers.
       We previously reported a novel method to detect HIV infected children
       using HIV-specific IgG3 antibodies (aHIV-G3). Now we report the result
       of a prospective study of aHIV-G3 in newborns of seropositive mothers
       and their concordance with infection status. PATIENTS AND METHODS: 31
       consecutive children born to HIV-positive mothers were enrolled. All of
       them were first tested during the first 15 days of life and then
       retested by the age of 3 months. Results were compared with infection
       status defined as serum negativization or confirmed diagnosis of HIV
       infection assessed by conventional serological tests, PCR and virus
       isolation. aHIV-G3 assay was performed using a commercial kit (Bio Rad,
       Richmond CA) modified with overnight incubation with serum and FBS and
       than matched with IgG specific antibodies. Anti-mouse IgG MoAb alkaline
       phosphatase coniugated was finally used. RESULTS: Of the 18/31 (58%) pts
       who were aHIV-G3 negative at birth, 16 remained negative and are
       non-infected, 1 became aHIV-G3 positive at 3 months and is infected, and
       1 died at 3 months of progressive disease with total IgG3 levels < 3rd
       percentile. Of the 13/31 (42%) pts who tested positive at birth, 5
       remained G3 positive troughout the study period and were documented to
       be infected, while the 8 who seroreverted cleared aHIV-G3 at a median
       age of 2 months (range 1-8 months). CONCLUSION: This prospective study
       confirmed that aHIV-G3 is a novel, simple, low-technology, low cost
       assay that, when performed at birth and at 3 months, predicted correct
       infection status in 28/31 pts (90%). Late (3 to 8 months) aHIV-G3
       clearance and AIDS-dependent IgG3 depletion were possible pitfalls.
 DE    *AIDS Serodiagnosis  Female  Follow-Up Studies  Human  HIV
       Antibodies/*BLOOD  HIV Infections/*DIAGNOSIS/IMMUNOLOGY/TRANSMISSION
       HIV Seronegativity/*IMMUNOLOGY  IgG/*BLOOD  Infant  Infant, Newborn
       Italy  Predictive Value of Tests  Pregnancy  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).